Table of Contents

State/Territory Name: Hawaii

State Plan Amendment (SPA) #: 22-0007

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) CMS 179 Form/Summary Form (with 179-like data)
- 3) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-26-12 Baltimore, Maryland 21244-1850



February 3, 2023

Judy Mohr Peterson, PhD Med-QUEST Division Administrator Office of the Director Department of Human Services PO Box 339 Honolulu, HI 96809-0339

Re: Hawaii State Plan Amendment (SPA) 22-0007

Dear Dr. Mohr Peterson:

The Centers for Medicare & Medicaid Services (CMS) reviewed the proposed Medicaid State Plan Amendment (SPA) submitted under transmittal number (TN) 22-0007. This amendment proposes to attest to the state's coverage of COVID-19 vaccines and vaccine administration, COVID-19 testing, and COVID-19 treatment, as required by sections 1905(a)(4)(E) and 1905(a)(4)(F) of the Social Security Act (Act).

Pursuant to section 1135(b)(5) of the Act, for the period of the public health emergency, CMS is modifying the requirement at 42 C.F.R. §430.20 that the state submit SPAs related to the COVID-19 public health emergency by the final day of the quarter, to obtain a SPA effective date during the quarter, enabling SPAs submitted after the last day of the quarter to have an effective date in a previous quarter, but no earlier than the effective date of the public health emergency.

The State of Hawaii also requested a waiver to modify the public notice requirements applicable to the SPA submission process. Pursuant to section 1135(b)(5) of the Act, CMS is modifying public notice requirements applicable to the SPA submission process. Public notice for SPAs is required under 42 C.F.R. §447.205 for changes in statewide methods and standards for setting Medicaid payment rates, 42 C.F.R. §447.57 for changes to premiums and cost sharing, and 42 C.F.R. §440.386 for changes to Alternative Benefit Plans (ABPs). Pursuant to section 1135(b)(5) of the Act, CMS is approving the state's request to modify these notice requirements otherwise applicable to SPA submissions.

CMS conducted our review of your submittal according to statutory requirements in Title XIX of the Act and implementing regulations. This letter is to inform you that Hawaii's Medicaid SPA Transmittal Number 22-0007 is approved effective March 11, 2021.

If you have any questions, please contact Brian Zolynas at 415-744-3601 or via email at Brian.Zolynas@cms.hhs.gov.

Sincerely,

Alissa M.
Deboy -S

Deboy -S

Date: 2023.02 03
07:18:02 -05'00'

Alissa Mooney DeBoy On Behalf of Anne Marie Costello, Deputy Director Center for Medicaid and CHIP Services

Enclosures

cc: Jodeen Enesa, Med-QUEST

Cori Kekina, Med-QUEST Edie Mayeshiro, Med-QUEST

CENTERIO FOR MEDIO INC. A MEDIO ID CENTOCO	4	0.07475		
TRANSMITTAL AND NOTICE OF APPROVAL OF	1. TRANSMITTAL NUMBER 2 2 — 0 0 0 7	2. STATE HI		
STATE PLAN MATERIAL				
FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES	3. PROGRAM IDENTIFICATION: TITLE OF SECURITY ACT			
	SECURITY ACT (XIX () XXI		
TO: CENTER DIRECTOR	4. PROPOSED EFFECTIVE DATE			
CENTERS FOR MEDICAID & CHIP SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES	March 11, 20			
5. FEDERAL STATUTE/REGULATION CITATION	6. FEDERAL BUDGET IMPACT (Amount a FFY 2022 \$ 82,0			
American Rescue Plan Act of 2021 Title XIX of the Social Security Act and Section 1135 of the Social Security Act				
7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT	8. PAGE NUMBER OF THE SUPERSED			
Attachment 7.7-A pg. 1-3	OR ATTACHMENT (If Applicable)			
Attachment 7.7-B pg. 1-3	NEW			
Attachment 7.7-C pg. 1-3				
9. SUBJECT OF AMENDMENT				
COVID-19 American Rescue Plan Act: Vaccine, Vaccine Administr	ration Treatment and Testing			
To American resource fair Act. Vaccine, Vaccine Administra	ation, Treatment and Testing.			
10. GOVERNOR'S REVIEW (Check One)				
GOVERNOR'S OFFICE REPORTED NO COMMENT	OTHER, AS SPECIFIED:			
COMMENTS OF GOVERNOR'S OFFICE ENCLOSED				
NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL				
14 SIGNATURE OF STATE AGENCY OFFICIAL	5. RETURN TO			
	State of Hawaii			
12. TYPED NAME	Department of Human Services Office of the Director			
Judy Monr Peterson, PhD	P.O. Box 339			
13. TITLE Med-QUEST Division Administrator	lonolulu, Hawaii 96809-0339			
14. DATE SUBMITTED				
07/22/22				
FOR CMS US				
16. DATE RECEIVED July 22, 2022	7. DATE APPROVED February 3, 2023			
PLAN APPROVED - ON	• •			
	9. SAGNATURE OF A PEROVING OFFICIA	L		
March 11, 2021	Deboy -S Date: 2023 02.03 07:18:18-05:00'			
20. TYPED NAME OF APPROVING OFFICIAL 2	1. TITLE OF APPROVING OFFICIAL			
Alissa Mooney DeBoy on Behalf of Anne Marie Costello	Acting Director, Center for Medicaid and	CHIP Services		
22. REMARKS				
	Day 9 an 10/06/2022			
•	State authorized pen and ink change to Box 5 on 01/30/2023 and to Box 8 on 10/06/2022. Box 5: CMS made a pen and ink change on 2/1/23 to add Sec. 1135 citation.			
201 5. Citio made a pen and mix change on 2/1/25 to add 5cc. 1155				

Vaccine and Vaccine Administration at Section 1905(a)(4)(E) of the Social Security Act

During the period starting March 11, 2021 and ending on the last day of the first calendar quarter that begins one year after the last day of the emergency period described in section 1135(g)(1)(B) of the Social Security Act (the Act):

c-				
LO	ve	ra	ae	

X The state assures coverage of COVID-19 vaccines and administration of the vaccines. ¹
X The state assures that such coverage:
 Is provided to all eligibility groups covered by the state, including the optional Individuals Eligible for Family Planning Services, Individuals with Tuberculosis, and COVID-19 groups if applicable, with the exception of the Medicare Savings Program groups and the COBRA Continuation Coverage group for which medical assistance consists only of payment of premiums; and Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(H) and section 1916A(b)(3)(B)(xii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.
\underline{X} Applies to the state's approved Alternative Benefit Plans, without any deduction, cost sharing or similar charge, pursuant to section 1937(b)(8)(A) of the Act.
\underline{X} The state provides coverage for any medically necessary COVID-19 vaccine counseling for children under the age of 21 pursuant to §§1902(a)(11), 1902(a)(43), and 1905(hh) of the Act.
X The state assures compliance with the HHS COVID-19 PREP Act declarations and authorizations, including all of the amendments to the declaration, with respect to the providers that are considered qualified to prescribe, dispense, administer, deliver and/or distribute COVID-19 vaccines.
Additional Information (Optional):

Supersedes TN: <u>NEW</u>

¹ The vaccine will be claimed under this benefit once the federal government discontinues purchasing the vaccine. TN: $\underline{22\text{-}0007}$ Approval Date: $\underline{02/03/2023}$ Effective Date: $\underline{03/11/2021}$

Reimbursement

 \underline{X} The state assures that the state plan has established rates for COVID-19 vaccines and the administration of the vaccines for all qualified providers pursuant to sections 1905(a)(4)(E) and 1902(a)(30)(A) of the Act.

List Medicaid state plan references to payment methodologies that describe the rates for COVID-19 vaccines and their administration for each applicable Medicaid benefit:

(language below approved in HI-SPA 21-0008)

Payment for COVID-19 vaccine administered by licensed pharmacist, pharmacy interns or pharmacy technicians shall be made to the affiliated billing provider/pharmacy in accordance with the same reimbursement methodologies and rates developed for the specific type of providers and/or services described elsewhere in the State Plan and listed below.

Hawaii sets the following rates for COVID-19 vaccine administration: \$30.68 for single dose vaccines, and \$18.59 for the first dose and \$30.68 for the second dose for vaccines requiring two doses from 1/15/21 to 3/31/21. Starting 4/1/21 the COVID-19 vaccine administration rate will be \$43.68 per dose until the end of the PHE.

Hawaii sets the following rate for COVID-19 HOME VACCINE ADMINISTRATION code M0201 at \$60.00 until the end of the PHE. This methodology is based on paying approximately 69.01% above the current Medicare rate of \$35.50 for code M0201.

The state is establishing rates for COVID-19 vaccines and the administration of the vaccines pursuant to sections 1905(a)(4)(E) and 1902(a)(30)(A) of the Act.
The state's rates for COVID-19 vaccines and the administration of the vaccines are consistent with Medicare rates for COVID-19 vaccines and the administration of the vaccines, including any future Medicare updates at the: Medicare national average, OR Associated geographically adjusted rate.
\underline{X} The state is establishing a state specific fee schedule for COVID-19 vaccines and the administration of the vaccines pursuant to sections 1905(a)(4)(E) and 1902(a)(30)(A) of the Act.
The state's rate is as follows and the state's fee schedule is published in the following location:
Hawaii will revert back to the pre-PHE vaccine rate of \$4.00 per dose after the PHE ends.
The state's fee schedule is the same for all governmental and private providers.
The below listed providers are paid differently from the above rate schedules and payment to these providers for COVID-19 vaccines and the administration of the vaccines are described under the benefit payment methodology applicable to the provider type:

TN: <u>22-0007</u> Approval Date: <u>02/03/2023</u> Effective Date: <u>03/11/2021</u>

The payment methodologies for COVID-19 vaccines and the administration of the vaccines for providers listed above are described below:
_XThe state is establishing rates for any medically necessary COVID-19 vaccine counseling for children under the age of 21 pursuant to sections $1905(a)(4)(E)$, $1905(r)(1)(B)(v)$ and $1902(a)(30)(A)$ of the Act.
X_The state's rate is as follows and the state's fee schedule is published in the following location :

60310	Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service, 5 to 15 mins time. (This code is used for Medicaid billing purposes.)	\$9.17
0311	Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service, 16-30 mins time. (This code is used for Medicaid billing purposes.)	\$24.13
60312	Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 5 to 15 mins time. (This code is used for Medicaid billing purposes.)	\$9.17
60313	Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 16-30 mins time. (This code is used for Medicaid billing purposes.)	\$24.13
G0314	Immunization counseling by a physician or other qualified health care professional for COVID-19, ages under 21, 16-30 mins time. (This code is used for the Medicaid Early and Periodic Screening, Diagnostic, and Treatment Benefit (EPSDT).	\$24.13
60315	Immunization counseling by a physician or other qualified health care professional for COVID-19, ages under 21, 5-15 mins time. (This code is used for the Medicaid Early and Periodic Screening, Diagnostic, and Treatment Benefit (EPSDT)	\$9.17

The COVID-19 stand-alone vaccine counseling codes rates are listed above.

PRA Disclosure Statement Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 75). Public burden for all of the collection of information requirements under this control number is estimated to take up to 1 hour per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

TN: <u>22-0007</u> Approval Date: <u>02/03/2023</u> Effective Date: <u>03/11/2021</u>

COVID-19 Testing at section 1905(a)(4)(F) of the Social Security Act

During the period starting March 11, 2021 and ending on the last day of the first calendar quarter that begins one year after the last day of the emergency period described in section 1135(g)(1)(B) of the Social Security Act (the Act):

_						
(റ	v	P	ra	n	P

 \underline{X} The states assures coverage of COVID-19 testing consistent with the Centers for Disease Control and Prevention (CDC) definitions of diagnostic and screening testing for COVID-19 and its recommendations for who should receive diagnostic and screening tests for COVID-19.

X The state assures that such coverage:

- 1. Includes all types of FDA authorized COVID-19 tests;
- 2. Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits;
- 3. Is provided to the optional COVID-19 group if applicable; and
- 4. Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(I) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.

Please describe any limits on amount, duration or scope of COVID-19 testing consistent with 42 CFR 440.230(b).

8 COVID Home Test Kits per individual, per month. This limitation may be exceeded based upon medical necessity.

X Applies to the state's approved Alternative Benefit Plans, without any deduction, cost sharing, or similar charge, pursuant to section 1937(b)(8)(B) of the Act.

 \underline{X} The state assures compliance with the HHS COVID-19 PREP Act declarations and authorizations, including all of the amendments to the declaration.

Additional Information (Optional):

TN: <u>22-0007</u> Approval Date: <u>02/03/2023</u> Effective Date: <u>03/11/2021</u>

Reimbursement

The state assures that it has established state plan rates for COVID-19 testing consistent with the CDC definitions of diagnostic and screening testing for COVID-19 and its recommendations for who should receive diagnostic and screening tests for COVID-19.
List references to Medicaid state plan payment methodologies that describe the rates for COVID-19 testing for each applicable Medicaid benefit:
\underline{X} The state is establishing rates for COVID-19 testing pursuant to pursuant to sections 1905(a)(4)(F) and 1902(a)(30)(A) of the Act.
_X The state's rates for COVID-19 testing are consistent with Medicare rates for testing, including any future Medicare updates at the:
Medicare national average, ORX Associated geographically adjusted rate.
\underline{X} The state is establishing a state specific fee schedule for COVID-19 testing pursuant to sections 1905(a)(4)(F) and 1902(a)(30)(A) of the Act.
The state's rate is as follows and the state's fee schedule is published in the following location :
The state is establishing the Medicare rate for COVID-19 testing (except home tests) from March 11, 2021 to the last day of the ARP coverage period.
Payment for home antigen test is \$12. Hawaii will not pay a dispensing fee. The state will revert back to the pre-PHE vaccine rate (\$4/dose) after the PHE ends.
The state's fee schedule is the same for all governmental and private providers.

TN: <u>22-0007</u> Approval Date: <u>02/03/2023</u> Effective Date: <u>03/11/2021</u>

	payment to these providers for COVID-19 testing is described under the benefit payment methodology applicable to the provider type:
Additio	nal Information (Optional):
	The payment methodologies for COVID-19 testing for providers listed above are described below:

PRA Disclosure Statement Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 75). Public burden for all of the collection of information requirements under this control number is estimated to take up to 1 hour per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

TN: <u>22-0007</u> Approval Date: <u>02/03/2023</u> Effective Date: <u>03/11/2021</u>

COVID-19 Treatment at section 1905(a)(4)(F) of the Social Security Act

During the period starting March 11, 2021 and ending on the last day of the first calendar quarter that begins one year after the last day of the emergency period described in section 1135(g)(1)(B) of the Social Security Act (the Act):

Coverage for the Treatment and Prevention of COVID

X_ The stat	te assures that such coverage:
1.	Includes any non-pharmacological item or service described in section 1905(a) of the Act, that is medically necessary for treatment of COVID-19;
2.	Includes any drug or biological that is approved (or licensed) by the U.S. Food & Drug Administration (FDA) or authorized by the FDA under an Emergency Use Authorization (EUA) to treat or prevent COVID-19, consistent with the applicable authorizations;
3.	Is provided without amount, duration or scope limitations that would otherwise apply when covered for purposes other than treatment or prevention of COVID-19
4.	Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits;
5.	Is provided to the optional COVID-19 group, if applicable; and
6.	Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(l) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.
	Applies to the state's approved Alternative Benefit Plans, without any deduction, sharing, or similar charge, pursuant to section 1937(b)(8)(B) of the Act.
	te assures compliance with the HHS COVID-19 PREP Act declarations and ons, including all of the amendments to the declaration.

TN: <u>22-0007</u> Approval Date: <u>02/03/2023</u> Effective Date: <u>03/11/2021</u>

Coverage for a Condition that May Seriously Complicate the Treatment of COVID

X The state assures coverage of treatment for a condition that may seriously complicate the treatment of COVID-19 during the period when a beneficiary is diagnosed with or is presumed to have COVID-19.

X The state assures that such coverage:

- 1. Includes items and services, including drugs, that were covered by the state as of March 11, 2021;
- 2. Is provided without amount, duration or scope limitations that would otherwise apply when covered for other purposes;
- 3. Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits;
- 4. Is provided to the optional COVID-19 group, if applicable; and
- 5. Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(I) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.
- \underline{X} Applies to the state's approved Alternative Benefit Plans, without any deduction, cost sharing, or similar charge, pursuant to section 1937(b)(8)(B) of the Act.
- X The state assures compliance with the HHS COVID-19 PREP Act declarations and authorizations, including all of the amendments to the declaration.

F	Additional Information (Optional):

Reimbursement

X The state assures that it has established state plan rates for COVID-19 treatment, including specialized equipment and therapies (including preventive therapies).

List references to Medicaid state plan payment methodologies that describe the rates for COVID-19 treatment for each applicable Medicaid benefit:

COVID-19 Treatment Definition:

Hawaii will pay the Medicare geographic rate for monoclonal antibody infusion treatment.

When this SPA coverage period ends, Hawaii will revert to the payment methodology for the Hawaii Medicaid Fee Schedule listed on Attachment 4.19-B pg.1.

For other COVID-treatments related to COVID-19, Hawaii will pay pursuant to payment methodology existing in state plan.

TN: <u>22-0007</u> Approval Date: <u>02/03/2023</u> Effective Date: <u>03/11/2021</u>

	e is establishing rates or fee schedule for COVID-19 treatment, including specialized d therapies (including preventive therapies) pursuant to sections 1905(a)(4)(F) and) of the Act.
	The state's rates or fee schedule is the same for all governmental and private providers.
	The below listed providers are paid differently from the above rate schedules and payment to these providers for COVID-19 vaccines and the administration of the vaccines are described under the benefit payment methodology applicable to the provider type:
Additional Info	ormation (Optional):

PRA Disclosure Statement Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 75). Public burden for all of the collection of information requirements under this control number is estimated to take up to 1 hour per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

TN: <u>22-0007</u> Approval Date: <u>02/03/2023</u> Effective Date: <u>03/11/2021</u>